Drug discovery and development company e-Therapeutics said annual losses narrowed and it remains confident of becoming cash generative.For the year ended 31 January loss before tax narrowed to £1.96m from a loss of £2.2m the year before. Revenue increased to £67,000 from £64,000 the previous year."We are confident that we can achieve our goal of becoming a cash-generative business and provide valuable returns for our shareholders," the group said in Monday's company statement.The group added that it "has a healthy pipeline of products in development and it will continue to drive these forward, whilst maintaining a prudent eye on expenditure."